{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:24:48Z","timestamp":1772166288884,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["21K15818"],"award-info":[{"award-number":["21K15818"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0\u20121.0, 1.5\u20122.0, 2.5\u20123.0, and 3.5\u20124.0) were 5.5, 14.8, 28.3, and 39.0\u00a0months (p\u2009&lt;\u20090.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0\u20121.0, 1.5\u20122.0, and 2.5\u20123.0) were 3.2, 11.0, and 16.0\u00a0months (p\u2009=\u20090.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6\u00a0months with and without osimertinib, respectively (p\u2009=\u20090.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p\u2009=\u20090.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3\u00a0months for the high-, low- and no-expression groups (p\u2009=\u20090.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6\u00a0months) than those without (median OS, 3.6\u00a0months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-023-02218-3","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:02:56Z","timestamp":1675728176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors\u2014retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Hajime","family":"Higaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Shido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Minatogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Takashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Uchinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"issue":"10","key":"2218_CR1","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/cncr.10541","volume":"94","author":"LJ Schouten","year":"2002","unstructured":"Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698\u2013705.","journal-title":"Cancer"},{"issue":"14","key":"2218_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865\u201372.","journal-title":"J Clin Oncol"},{"key":"2218_CR3","doi-asserted-by":"crossref","unstructured":"Carden CP, Agarwal R, Saran F, Judson IR. Personal view eligibility of patients with brain metastases for phase I trials: Time for a rethink? [Internet]. Vol. 9, www.thelancet.com\/oncology. 2008. Available from: www.thelancet.com\/oncology","DOI":"10.1016\/S1470-2045(08)70257-2"},{"issue":"4","key":"2218_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","volume":"1","author":"H Aoyama","year":"2015","unstructured":"Aoyama H, Tago M, Shirato H. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015;1(4):457\u201364.","journal-title":"JAMA Oncol"},{"issue":"32","key":"2218_CR5","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2218_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/nou099","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015;17(1):122\u20138.","journal-title":"Neuro Oncol"},{"issue":"6","key":"2218_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827\u201331.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2218_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11060-018-2958-6","volume":"140","author":"SR Rice","year":"2018","unstructured":"Rice SR, Bentzen SM, Hanna A, Choi E, Boggs DH, Kwok Y, et al. Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. J Neurooncol. 2018;140(2):341\u20139.","journal-title":"J Neurooncol"},{"key":"2218_CR9","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2218_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-020-03657-8","volume":"151","author":"KY Fan","year":"2021","unstructured":"Fan KY, Lalani N, LeVasseur N, Krauze A, Hsu F, Gondara L, et al. Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy. J Neurooncol. 2021;151(2):231\u201340.","journal-title":"J Neurooncol"},{"issue":"7","key":"2218_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976\u201383.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2218_CR12","first-page":"156","volume":"4","author":"T Kohno","year":"2015","unstructured":"Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4(2):156\u201364.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2218_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-017-0844-6","volume":"12","author":"C Nieder","year":"2017","unstructured":"Nieder C, Hintz M, Oehlke O, Bilger A, Grosu AL. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiat Oncol. 2017;12(1):1\u20136.","journal-title":"Radiat Oncol"},{"key":"2218_CR14","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/OTT.S288928","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Jing W, Zhai X, Jia W, Zhu H, Yu J. Estimating survival in patients with non-small-cell lung cancer and brain metastases: a verification of the graded prognostic assessment for lung cancer using molecular markers (lung-molgpa). Onco Targets Ther. 2021;14:1623\u201332.","journal-title":"Onco Targets Ther"},{"key":"2218_CR15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.2016.71.5706","volume":"35","author":"JM William","year":"2017","unstructured":"William JM, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of brain metastases in tyrosine kinaseinhibitor\u2013na \u0308ive epidermal growth factor receptor\u2013mutantnon\u2013small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol Am Soc Clin Oncol. 2017;35:1033\u20135.","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"issue":"10183","key":"2218_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019;393(10183):1819\u201330.","journal-title":"The Lancet"},{"issue":"3","key":"2218_CR17","first-page":"462","volume":"7","author":"ZK Pan","year":"2015","unstructured":"Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7(3):462\u201370.","journal-title":"J Thorac Dis"},{"key":"2218_CR18","doi-asserted-by":"crossref","unstructured":"Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. In: Lung cancer. Vol. 112, Elsevier Ireland Ltd; 2017. p. 200\u201315.","DOI":"10.1016\/j.lungcan.2017.08.005"},{"issue":"1","key":"2218_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"PW Sperduto","year":"2022","unstructured":"Sperduto PW, De B, Li J, Carpenter D, Kirkpatrick J, Milligan M, et al. Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors. Int J Radiat Oncol Biol Phys. 2022;114(1):60\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02218-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02218-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:14:15Z","timestamp":1675728855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02218-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02218-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1708831\/v1","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Hokkaido Cancer Center Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}